HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hull, R. L. Articles by Kahn, S. E. Search for Related Content PubMed PubMed Citation Articles by Hull, R. L. Articles by Kahn, S. E. Social Bookmarking                What's this?

Increased Dietary Fat Promotes Islet Amyloid Formation and ß-Cell Secretory Dysfunction in a Transgenic Mouse Model of Islet Amyloid

From the Division of Metabolism, Endocrinology and Nutrition, Department of Medicine, VA Puget Sound Health Care System and University of Washington, Seattle, Washington

Transgenic mice expressing the amyloidogenic human islet amyloid polypeptide (hIAPP) in their islet ß-cells are a model of islet amyloid formation as it occurs in type 2 diabetes. Our hIAPP transgenic mice developed islet amyloid when fed a breeder chow but not regular chow. Because the breeder chow contained increased amounts of fat, we hypothesized that increased dietary fat enhances islet amyloid formation. To test this hypothesis, we fed male hIAPP transgenic and nontransgenic control mice diets containing 15% (low fat), 30% (medium fat), or 45% (high fat) of calories derived from fat for 12 months, and we measured islet amyloid, islet endocrine cell composition, and ß-cell function. Increased dietary fat in hIAPP transgenic mice was associated with a dose-dependent increase in both the prevalence (percentage of islets containing amyloid deposits; 34 ± 8, 45 ± 8, and 58 ± 10%, P < 0.05) and severity (percentage of islet area occupied by amyloid; 0.8 ± 0.5, 1.0 ± 0.5, and 4.6 ± 2.5%, P = 0.05) of islet amyloid. In addition, in these hIAPP transgenic mice, there was a dose-dependent decrease in the proportion of islet area comprising ß-cells, with no significant change in islet size. In contrast, nontransgenic mice adapted to diet-induced obesity by increasing their islet size more than twofold. Increased dietary fat was associated with impaired insulin secretion in hIAPP transgenic (P = 0.05) but not nontransgenic mice. In summary, dietary fat enhances both the prevalence and severity of islet amyloid and leads to ß-cell loss and impaired insulin secretion. Because both morphologic and functional defects are present in hIAPP transgenic mice, this would suggest that the effect of dietary fat to enhance islet amyloid formation might play a role in the pathogenesis of the islet lesion of type 2 diabetes in humans.

CiteULike

Del.icio.us

Digg

Reddit

Technorati

This article has been cited by other articles:

				S. Bonner-Weir and T. D. O'Brien Islets in Type 2 Diabetes: In Honor of Dr. Robert C. Turner Diabetes, November 1, 2008; 57(11): 2899 - 2904. [Full Text] [PDF]

				M. R. Hayden, P. R. Karuparthi, J. Habibi, G. Lastra, K. Patel, C. Wasekar, C. M. Manrique, U. Ozerdem, S. Stas, and J. R. Sowers Ultrastructure of Islet Microcirculation, Pericytes and the Islet Exocrine Interface in the HIP Rat Model of Diabetes Experimental Biology and Medicine, September 1, 2008; 233(9): 1109 - 1123. [Abstract] [Full Text] [PDF]

				D. A. Nugent, D. M. Smith, and H. B. Jones A Review of Islet of Langerhans Degeneration in Rodent Models of Type 2 Diabetes Toxicol Pathol, June 1, 2008; 36(4): 529 - 551. [Abstract] [Full Text] [PDF]

				R. L. Hull, S. Zraika, J. Udayasankar, R. Kisilevsky, W. A. Szarek, T. N. Wight, and S. E. Kahn Inhibition of glycosaminoglycan synthesis and protein glycosylation with WAS-406 and azaserine result in reduced islet amyloid formation in vitro Am J Physiol Cell Physiol, November 1, 2007; 293(5): C1586 - C1593. [Abstract] [Full Text] [PDF]

				M. R. Hayden, P. R. Karuparthi, C. M. Manrique, G. Lastra, J. Habibi, and J. R. Sowers A BRIEF COMMUNICATION: Longitudinal Ultrastructure Study of Islet Amyloid in the HIP Rat Model of Type 2 Diabetes Mellitus Experimental Biology and Medicine, June 1, 2007; 232(6): 772 - 779. [Abstract] [Full Text] [PDF]

				S. Zraika, R. L. Hull, J. Udayasankar, A. Clark, K. M. Utzschneider, J. Tong, F. Gerchman, and S. E. Kahn Identification of the Amyloid-Degrading Enzyme Neprilysin in Mouse Islets and Potential Role in Islet Amyloidogenesis Diabetes, February 1, 2007; 56(2): 304 - 310. [Abstract] [Full Text] [PDF]

				R. L. Hull, M. R. Watts, K. Kodama, Z.-p. Shen, K. M. Utzschneider, D. B. Carr, J. Vidal, and S. E. Kahn Genetic background determines the extent of islet amyloid formation in human islet amyloid polypeptide transgenic mice Am J Physiol Endocrinol Metab, October 1, 2005; 289(4): E703 - E709. [Abstract] [Full Text] [PDF]

				R. L. Hull, Z.-P. Shen, M. R. Watts, K. Kodama, D. B. Carr, K. M. Utzschneider, S. Zraika, F. Wang, and S. E. Kahn Long-Term Treatment With Rosiglitazone and Metformin Reduces the Extent of, but Does Not Prevent, Islet Amyloid Deposition in Mice Expressing the Gene for Human Islet Amyloid Polypeptide Diabetes, July 1, 2005; 54(7): 2235 - 2244. [Abstract] [Full Text] [PDF]

				R. L. Hull, G. T. Westermark, P. Westermark, and S. E. Kahn Islet Amyloid: A Critical Entity in the Pathogenesis of Type 2 Diabetes J. Clin. Endocrinol. Metab., August 1, 2004; 89(8): 3629 - 3643. [Abstract] [Full Text] [PDF]

				R. A. Ritzel and P. C. Butler Replication Increases {beta}-Cell Vulnerability to Human Islet Amyloid Polypeptide-Induced Apoptosis Diabetes, July 1, 2003; 52(7): 1701 - 1708. [Abstract] [Full Text] [PDF]